PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11819727-0	2001	Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.	smmc	31-35	vascular endothelial growth factor A	Homo sapiens	59-93	
25607114-0	2015	Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor.	smmc	14-18	vascular endothelial growth factor A	Homo sapiens	78-82	
25607114-3	2015	Increased levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) were observed when SMMC-7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide-induced DNA damage, as indicated by the failure of upregulation of gammaHA2X.	smmc	130-134	vascular endothelial growth factor A	Homo sapiens	69-103	
25607114-3	2015	Increased levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) were observed when SMMC-7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide-induced DNA damage, as indicated by the failure of upregulation of gammaHA2X.	smmc	130-134	vascular endothelial growth factor A	Homo sapiens	105-109	
14966912-8	2004	The apoptotic rate of hepatocarcinoma SMMC-7721 cells was significantly promoted (17.98+/-0.86% vs 4.86+/-0.27%, P<0.01) and the survival rate was notably decreased (80.99+/-3.20% vs 93.52+/-3.93%, P<0.05) due to antisense VEGF(165) by flow cytometry (FCM).	smmc	38-42	vascular endothelial growth factor A	Homo sapiens	229-233